Loading organizations...
§ Venture Capital · Singapore, Central Region, Singapore
Singapore state-backed venture capital and private equity for biomedical sciences companies, now integrated into EDBI.
BioOne Capital operates as a corporate venture capital arm, specializing in strategic investments within the biomedical sciences and healthcare sectors. It provides capital and leverages its parent organization's resources, accelerating the growth of innovative companies. The firm identifies and supports high-potential ventures aligned with Singapore's national development goals.
Established in 2001, BioOne Capital was founded as a dedicated corporate venture arm of EDBI Investments, Singapore’s Economic Development Board’s investment branch. Its inception stemmed from the strategic insight that targeted capital deployment would bolster Singapore's biomedical ecosystem, fostering innovation and attracting leading life science companies. Swee-Yeok Chu held a key leadership role.
BioOne Capital primarily serves innovative biomedical and healthcare startups, offering essential funding and strategic guidance. Its efforts also benefit the broader Singaporean economy by cultivating a robust life sciences industry. The firm’s long-term vision positions Singapore as a global hub for advanced medical technologies and therapies.
Bio*One Capital has 5 tracked investments across 4 companies. The latest tracked deal is $104.0M Other Equity / Series E in Revance Therapeutics in April 2013.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Apr 2, 2013 | Revance Therapeutics | $104.0M Other Equity / Series E | — | Delphi Ventures, Novaquest Capital Management, PAC Link Ventures, Palo Alto Investors, Shepherd Ventures, Technology Partners, Vivo Ventures |
| Oct 11, 2010 | TriReme Medical | $17.0M Series D | Bio*one Capital | Adams Street Partners, Three Arch Partners |
| Jan 1, 2010 | Revance Therapeutics | $26.0M Series D | — | Vivo Capital, PAC Link Ventures, Palo Alto Investors, Shepherd Ventures, Technology Partners, Vivo Ventures |
| Dec 1, 2009 | FORMA Therapeutics | $3.0M Series B | Steve Hall | Cubist Pharmaceuticals, Novartis |
| Dec 5, 2008 | Broncus Technologies | $38.0M Other Equity | Ares Life Sciences | Abingworth, Broncus Technologies, Charter Ventures, HBM Healthcare Investments, JAIC America, Menlo Ventures, PAC Link Ventures, Resuscitated, Saints Capital, Saratoga Ventures, Sightline Ventures |